Brief: Delcath Systems Highlights Clinical Program Presentations At Esmo Congress 2026 And Independent Data On Percutaneous Hepatic Perfusion In Liver-Dominant Metastatic Uveal Melanoma
Mon 22:55
BRIEF-Delcath Systems Highlights Clinical Program Presentations At Esmo Congress 2026 And Independent Data On Percutaneous Hepatic Perfusion In Liver-Dominant Metastatic Uveal Melanoma Oct 19 (Reuters) - Delcath Systems Inc DCTH.O:
DELCATH SYSTEMS HIGHLIGHTS CLINICAL PROGRAM PRESENTATIONS AT ESMO CONGRESS 2026 AND INDEPENDENT DATA ON PERCUTANEOUS HEPATIC PERFUSION IN LIVER-DOMINANT METASTATIC UVEAL MELANOMA
Source text: ID:nBw9JNrPFa
Further company coverage: DCTH.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Delcath Systems
See all newsBrief: Delcath Systems Highlights Clinical Program Presentations At Esmo Congress 2026 And Independent Data On Percutaneous Hepatic Perfusion In Liver-Dominant Metastatic Uveal Melanoma
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule
Delcath Systems Inc reports results for the quarter ended June 30 - Earnings Summary
Delcath Systems Q2 revenue rises, beats estimates
Delcath Systems Inc expected to post a loss of 9 cents a share - Earnings Preview